In summary, our research demonstrates that inhibiting TLR3, 7, and 9 in combination has mitigated the extent of intestinal inflammation exacerbated by EBV DNA in a mouse model of IBD. The gene discussed is TLR3; the disease is inflammatory bowel disease.